A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 [conatumumab] in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma.

Trial Profile

A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 [conatumumab] in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Conatumumab (Primary) ; Bortezomib; Vorinostat
  • Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 04 Mar 2014 According to ClinicalTrials.gov record, status changed from suspended to completed.
    • 01 Jul 2010 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 22 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top